Antileukotrienes - new way for treatment of allergic diseases. Antileukotrienes are the first class of antiasthmatic drugs offering completely new mechanism of action. They block the biological effects of leukotrienes potent inflamatory mediators either by inhibiting their synthesis - zileuton, or binding to leukotriene receptors - montelukast, zafirlukast and pranlukast. This paper presents an overview of pharmacodynamics, pharmacokinetics and drug interactions of these new compounds, concentrating on montelukast and zafirlukast which are available in Poland. Their efficacy in asthma and other allergic diseases is also discussed.